-
-
Overview
-
Sulbactam Sodium is an irreversible inhibitor of several bacterial penicillinases and cephalosporinases. In the presence of low concentrations of sulbactam, ampicillin and other β-lactams readily inhibit the growth of a variety of resistant bacteria that contain β-lactamases. Sulbactam was developed by Pfizer, Inc. and was first described in 1978.
Sulbactam Sodium used alone has weak antibacterial activity, with the notable exception of its potent effects on susceptible and resistant strains of Neisseria gonorrhoeae. Sulbactam Sodium appears to be somewhat less potent but markedly more stable (in aqueous solution) than the β-lactamase inhibitor clavulanic acid.
Sulbactam Sodium inhibits common β-lactamases but cannot interact with the AmpC cephalosporinase. It confers little protection against Pseudomonas, Citrobacter, Enterobacter, and Serratia, which often express this gene.Please contact us at for specific academic pricing.
Background
Sulbactam Sodium contains a β-lactam ring that binds strongly to β-lactamase at or near its activation site, thereby permanently inhibiting enzymatic activity. This action protects other β-lactam antibiotics (penicillins, cephalosporins, etc.) from β-lactamase catalysis, thereby enhancing their antibacterial activity.
Sulbactam also shows antibacterial activity against various strains, sulbactam able to bind to and inhibit penicillin binding proteins PBP1 and PBP3. This antibacterial activity varies depending on species.
-
- Properties
- Applications
-
Overview